(Q53995826)

23 May 2018

editorial

0 references

review article

1 reference

title

Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when? (English)

1 reference

23 May 2018

0 references

1 reference

Fontana RJ

1

1 reference

23 May 2018

Lok AS

series ordinal

2

1 reference

23 May 2018

publication date

1 August 2000

1 reference

23 May 2018

published in

Journal of Hepatology

1 reference

23 May 2018

volume

33

1 reference

23 May 2018

issue

2

1 reference

23 May 2018

page(s)

329-332

1 reference

23 May 2018

Hepatitis B: Evolving Epidemiology and Implications for Control

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Transection of the oesophagus for bleeding oesophageal varices

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Prognostic Value of Child-Turcotte Criteria in Medically Treated Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Survival in chronic hepatitis B. An analysis of 379 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980376-1

7 January 2021

10.1016/S0168-8278(00)80376-1

Identifiers

DOI

1 reference

23 May 2018

1 reference

23 May 2018